Bicycle Therapeutics
Bicycle Therapeutics' revenue rose 105.8% to $73 million in fiscal 2025. Its operating margin was −340.4%, up from −595.0% a year earlier. Free cash flow was −$252 million. The diluted share count rose 19.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Bicycle Therapeutics does
Bicycle Therapeutics is a drug developer, based in Cambridge, England, that has no approved medicines yet. Its experimental drugs are built from Bicycle molecules: small, lab-made chains of amino acids folded into two loops so they latch tightly onto a chosen target. It attaches them to a toxin that kills tumor cells, or to a radioactive payload, and is testing them mainly against cancer.
Its main candidate, nuzefatide pevedotin, is in clinical trials in patients with advanced solid tumors and pancreatic cancer. A radioactive candidate, BT1702, is in the safety studies needed before human trials can start. In March 2026 the company said it would scale back work on zelenectide pevedotin, a drug tested in bladder, breast and lung cancers, and stop developing a third drug, BT7480, on its own. It is cutting about 30% of its workforce.
So far its revenue has come from research deals with larger drug makers, including Bayer, Novartis, Ionis and Genentech, which pay it to find Bicycle molecules for their own programs. Collaboration revenue rose by $37.3 million in 2025, mostly because Novartis and Bayer ended deals and the remaining payments were counted. The company had $628.1 million in cash at the end of 2025 and 288 employees, 191 of them in the United Kingdom.
Its biggest risks, as it describes them
- A long history of losses, and the chance that it never becomes profitable.
- It depends on a few drug candidates that may fail in trials or never win approval.
- Its Bicycle drugs are a new kind of medicine and may face extra scrutiny from regulators.
- It may need to raise more money, which could dilute shareholders or force it to cut programs.
- Competitors may bring out cancer drugs that work better, are safer or cost less.
Income statement
Bicycle Therapeutics lost money in fiscal 2025: a net loss of $219 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 439 | 339 | 526 | 880 | 628 |
| Debt incl. finance leases | 30 | 30 | 31 | — | — |
| Net debt (negative means net cash) | −409 | −309 | −496 | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.1x | 0.1x | — | — |
| Interest coverage | −22.0x | −34.9x | −58.2x | −121.3x | −1,199.3x |
| Current ratio | 12.7x | 6.9x | 8.1x | 13.8x | 12.0x |
| Quick ratio | 12.7x | 6.9x | 8.1x | 13.8x | 12.0x |
Cash flow
Projections
Project Bicycle Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Bicycle Therapeutics shares on the open market, and 7 insiders sold $458,694, $63,505 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Kevin LeeChief Executive Officer, Director | Sold | 1,737 | $4.31 | $7,486 | Form 4 |
| Jul 6, 2026 | Michael SkynnerChief Scientific Officer | Sold | 532 | $4.31 | $2,293 | Form 4 |
| Jul 6, 2026 | Jennifer Scott PerryChief Operating Officer | Sold plan | 376 | $4.34 | $1,631 | Form 4 |
| Jul 6, 2026 | Michael Charles Ferguson HannayChief Prod & Supply Chain Off | Sold | 255 | $4.31 | $1,099 | Form 4 |
| Jul 6, 2026 | Travis Alvin ThompsonChief Financial Officer | Sold | 104 | $4.31 | $448 | Form 4 |
| Jul 2, 2026 | Kevin LeeChief Executive Officer, Director | Sold | 5,905 | $4.27 | $25,214 | Form 4 |
| Jul 2, 2026 | Michael SkynnerChief Scientific Officer | Sold | 1,859 | $4.27 | $7,938 | Form 4 |
| Jul 2, 2026 | Michael Charles Ferguson HannayChief Prod & Supply Chain Off | Sold | 1,506 | $4.27 | $6,431 | Form 4 |
| Jul 2, 2026 | Jennifer Scott PerryChief Operating Officer | Sold plan | 1,036 | $4.27 | $4,424 | Form 4 |
| Jul 2, 2026 | Travis Alvin ThompsonChief Financial Officer | Sold | 819 | $4.27 | $3,497 | Form 4 |
| Apr 6, 2026 | Kevin LeeChief Executive Officer, Director | Sold | 1,716 | $5.05 | $8,666 | Form 4 |
| Apr 6, 2026 | Michael SkynnerChief Scientific Officer | Sold | 525 | $5.05 | $2,651 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | — | — |
| Rule of 40 | −149.1% | −439.7% | −241.4% |
| Altman Z'' | 2.21 | 7.20 | 5.27 |
| Accruals ratio | −23.9% | −0.6% | 3.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 4 of 8 | — | — |
Compare
Put Bicycle Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics | FY25 | 105.8% | −340.4% | −347.2% | — | — | — | |
| Compugen | FY25 | 161.1% | 43.0% | 43.0% | — | — | — | Compare |
| Cellectis | FY25 | 75.8% | −45.3% | −57.2% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 2 | 7 | 14 | 10 | 12 | 14 | 27 | 35 | 73 |
| Revenue growth | — | 246.4% | 93.4% | −24.7% | 12.6% | 23.6% | 86.5% | 30.8% | 105.8% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 12 | 21 | 26 | 33 | 45 | 82 | 156 | 173 | 240 |
| Operating income | −16 | −22 | −26 | −52 | −66 | −117 | −190 | −210 | −247 |
| Net income | −16 | −22 | −31 | −51 | −67 | −113 | −181 | −169 | −219 |
| Diluted EPS (US$) | −48.81 | −49.78 | −2.77 | −2.66 | −2.67 | −3.80 | −5.08 | −2.90 | −3.16 |
| Diluted shares (millions) | 0 | 0 | 11 | 19 | 25 | 30 | 36 | 58 | 69 |
| Cash flow | |||||||||
| Cash from operations | −1 | −26 | −29 | −18 | −15 | −86 | −61 | −165 | −250 |
| Capital expenditure | 1 | 1 | 2 | 1 | 2 | 19 | 3 | 1 | 2 |
| Free cash flow | −3 | −27 | −30 | −19 | −17 | −105 | −64 | −166 | −252 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 3 | 6 | 12 | 27 | 32 | 38 | 40 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 68 | 0 | 0 | 0 | 439 | 339 | 526 | 880 | 628 |
| Debt incl. finance leases | — | — | — | 14 | 30 | 30 | 31 | — | — |
| Total assets | — | 82 | 110 | 161 | 480 | 411 | 595 | 957 | 718 |
| Total liabilities | — | 29 | 17 | 66 | 134 | 140 | 224 | 164 | 108 |
| Shareholders' equity | −47 | −70 | 93 | 96 | 346 | 271 | 371 | 793 | 610 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | −787.0% | −304.7% | −190.6% | −500.1% | −561.0% | −806.6% | −704.1% | −595.0% | −340.4% |
| Net margin | −789.3% | −306.1% | −221.8% | −490.9% | −571.2% | −779.4% | −669.7% | −479.2% | −301.7% |
| Free cash flow margin | −122.7% | −382.1% | −218.6% | −182.8% | −143.8% | −726.7% | −235.6% | −470.5% | −347.2% |
| Rule of 40 (growth + FCF margin) | — | −135.7% | −125.2% | −207.5% | −131.2% | −703.0% | −149.1% | −439.7% | −241.4% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −261.9% | −54.1% | −30.2% | −36.5% | −56.3% | −29.0% | −31.2% |
| Return on assets | — | — | −31.9% | −37.6% | −20.9% | −25.3% | −35.9% | −21.8% | −26.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |